Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells - PubMed (original) (raw)
Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells
S M Mariani et al. Eur J Immunol. 1998 May.
Free article
Abstract
Like other members of the TNF family, TRAIL/Apo-2 ligand induces apoptosis in sensitive target cells in a caspase-dependent fashion. We recently found that TRAIL may be constitutively expressed on the surface of mouse and human tumor cells of T and B origin. To define the pattern of TRAIL expression in normal immune cells, freshly isolated splenocytes, Concanavalin A/IL-2-activated T cells and lipopolysaccharide-activated B cells were analyzed by surface staining with or without secondary stimulation. Activated, but not resting, CD3+ cells expressed TRAIL in an activation-dependent fashion. Conversely, freshly isolated B220+ cells displayed surface TRAIL and CD95L that were retained following activation. Restimulation with the protein kinase C activator phorbol 12-myristate 13-acetate and the calcium ionophore ionomycin or an agonistic anti-CD3 monoclonal antibody induced significant up-regulation of surface TRAIL and CD95L in CD3+, TCRalphabeta cells with CD4+ or CD8+ phenotype. Similarly to CD95L, TRAIL up-regulation was protein synthesis dependent and cyclosporin A sensitive. These results indicate that both TRAIL and CD95L are displayed on the cell surface of activated immune cells and may thus represent complementary effector pathways in the regulatory functions of T and B cells.
Similar articles
- Differential regulation of the expression of CD95 ligand, receptor activator of nuclear factor-kappa B ligand (RANKL), TNF-related apoptosis-inducing ligand (TRAIL), and TNF-alpha during T cell activation.
Wang R, Zhang L, Zhang X, Moreno J, Luo X, Tondravi M, Shi Y. Wang R, et al. J Immunol. 2001 Feb 1;166(3):1983-90. doi: 10.4049/jimmunol.166.3.1983. J Immunol. 2001. PMID: 11160247 - Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand.
Chou AH, Tsai HF, Lin LL, Hsieh SL, Hsu PI, Hsu PN. Chou AH, et al. J Immunol. 2001 Aug 1;167(3):1347-52. doi: 10.4049/jimmunol.167.3.1347. J Immunol. 2001. PMID: 11466352 - TRAIL/Apo-2 ligand induces primary plasma cell apoptosis.
Ursini-Siegel J, Zhang W, Altmeyer A, Hatada EN, Do RK, Yagita H, Chen-Kiang S. Ursini-Siegel J, et al. J Immunol. 2002 Nov 15;169(10):5505-13. doi: 10.4049/jimmunol.169.10.5505. J Immunol. 2002. PMID: 12421926 - The role of activation-induced cell death in the differentiation of T-helper-cell subsets.
Roberts AI, Devadas S, Zhang X, Zhang L, Keegan A, Greeneltch K, Solomon J, Wei L, Das J, Sun E, Liu C, Yuan Z, Zhou JN, Shi Y. Roberts AI, et al. Immunol Res. 2003;28(3):285-93. doi: 10.1385/IR:28:3:285. Immunol Res. 2003. PMID: 14713720 Review. - Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody.
Yonehara S. Yonehara S. Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):393-402. doi: 10.1016/s1359-6101(02)00024-2. Cytokine Growth Factor Rev. 2002. PMID: 12220552 Review.
Cited by
- Immunologic aspects of preeclampsia.
Boulanger H, Bounan S, Mahdhi A, Drouin D, Ahriz-Saksi S, Guimiot F, Rouas-Freiss N. Boulanger H, et al. AJOG Glob Rep. 2024 Feb 9;4(1):100321. doi: 10.1016/j.xagr.2024.100321. eCollection 2024 Feb. AJOG Glob Rep. 2024. PMID: 38586611 Free PMC article. Review. - TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems.
Alizadeh Zeinabad H, Szegezdi E. Alizadeh Zeinabad H, et al. Cancers (Basel). 2022 Oct 19;14(20):5125. doi: 10.3390/cancers14205125. Cancers (Basel). 2022. PMID: 36291908 Free PMC article. Review. - Immunosuppressive Mechanisms of Regulatory B Cells.
Catalán D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillón JC, Aravena O. Catalán D, et al. Front Immunol. 2021 Apr 29;12:611795. doi: 10.3389/fimmu.2021.611795. eCollection 2021. Front Immunol. 2021. PMID: 33995344 Free PMC article. Review. - Cytotoxic Efficacy and Resistance Mechanism of a TRAIL and VEGFA-Peptide Fusion Protein in Colorectal Cancer Models.
Kopczynski M, Statkiewicz M, Cybulska M, Kuklinska U, Unrug-Bielawska K, Sandowska-Markiewicz Z, Grochowska A, Gajewska M, Kulecka M, Ostrowski J, Mikula M. Kopczynski M, et al. Int J Mol Sci. 2021 Mar 19;22(6):3160. doi: 10.3390/ijms22063160. Int J Mol Sci. 2021. PMID: 33808900 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials